United Kingdom Cardiometabolic Diseases Market 洞察
发布日期: 09 May 2026 | 报告格式: 电子版（PDF）
The United KingdomCardiometabolic DiseasesMarket is growing at an 9.17%CAGR, driven by obesity, diabetes, hypertension, aging population, NHS programs, GLP-1s, statins, SGLT2 inhibitors improving outcomes.
United Kingdom Cardiometabolic Diseases Market Insights Forecasts to 2035
- The United KingdomCardiometabolic Diseases Market Size Was Estimated at USD5.7Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around9.17% from 2025 to 2035
- The United Kingdom Cardiometabolic Diseases Market Size is Expected to ReachUSD 13.7Billion by 2035
Notable Insights for United Kingdom Cardiometabolic Diseases Market
- By disease type,diabetes mellitusdominated, accounting forapproximately 38%share in 2024, driven by rising Type 2 diabetes prevalence.
- By therapy class,antihyperglycemic agentsheldapproximately 34% share, supported by increasing adoption of GLP-1 and SGLT2 inhibitors.
- Around12% of the UKadult population is affected by Type 2 diabetes, with obesity prevalenceexceeding 25–28%.
- Nearly60% of patients receive long-term pharmacologicalmanagement combining cardiovascular and metabolic therapies.
下载电子书（目录）
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United KingdomCardiometabolic DiseasesMarket, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United KingdomCardiometabolic Diseases Market
- Novo Nordisk
- Eli Lilly and Company
- AstraZeneca
- Pfizer
- Sanofi
- Novartis
- Merck & Co.
- Bayer
- Johnson & Johnson
- Others
Recent Developments:
- In March 2026, NIHR and British Heart Foundation launched a £50 million consortium with nine UK universities to reduce cardiovascular diseaseinequalities by improving hypertension and cholesterol detection in high-risk groups.
- In March 2026, King’s College London and Imperial College London launched an £8 million BHF-funded PhD programmedto train researchers in AI and bioengineering, advancing cardiovascular disease research and innovation.
- InApril 2024, NIHR launched 14 HealthTech Research Centres,including a cardiovascular unit atGuy’s and St Thomas’ and King’s College London, advancing AI, imaging, and digital cardiovascular care innovation.
Market Segmentation:
United Kingdom Cardiometabolic Diseases Market, By Disease Type
- Diabetes Mellitus
- Obesity
- Cardiovascular Diseases
- Metabolic Syndrome
- Others
United Kingdom Cardiometabolic Diseases Market, By Drug Class
- Antihyperglycemics
- Antihypertensives
- Lipid-Lowering Agents
- GLP-1 Receptor Agonists
- SGLT2 Inhibitors
United Kingdom Cardiometabolic Diseases Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Clinics
United Kingdom Cardiometabolic Diseases Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Cardiometabolic Diseases Market is expected to grow steadily due to increasing obesity, diabetes, hypertension, and sedentary lifestyles. Experts highlight strong convergence between metabolic and cardiovascular therapies, with GLP-1 receptor agonists and SGLT2 inhibitors reshaping treatment approaches. NHS preventive programs and early screening initiatives are improving diagnosis rates. Advancements in multi-target therapies and personalized medicine are expected to significantly enhance long-term disease management and reduce cardiovascular and metabolic complications through 2035.